|  | 2020 | 2021 | 2022 |
| --- | --- | --- | --- |
|  | (N=1036) | (N=1887) | (N=2046) |
| Pre-vaccine HAI titre |  |  |  |
| 5 | 118 (11.4%) | 215 (11.4%) | 106 (5.2%) |
| 10 | 65 (6.3%) | 303 (16.1%) | 129 (6.3%) |
| 20 | 163 (15.7%) | 350 (18.5%) | 219 (10.7%) |
| 40 | 189 (18.2%) | 445 (23.6%) | 405 (19.8%) |
| 80 | 240 (23.2%) | 318 (16.9%) | 441 (21.6%) |
| 160 | 158 (15.3%) | 201 (10.7%) | 438 (21.4%) |
| 320 | 87 (8.4%) | 44 (2.3%) | 195 (9.5%) |
| 640 | 14 (1.4%) | 9 (0.5%) | 90 (4.4%) |
| 1280 | 2 (0.2%) | 2 (0.1%) | 23 (1.1%) |
| 2560 | 0 (0%) | 0 (0%) | 0 (0%) |
| Sex |  |  |  |
| Female | 854 (82.4%) | 1597 (84.6%) | 1725 (84.3%) |
| Male | 182 (17.6%) | 286 (15.2%) | 321 (15.7%) |
| Other | 0 (0%) | 4 (0.2%) | 0 (0%) |
| Age group (yrs) |  |  |  |
| <30 | 196 (18.9%) | 342 (18.1%) | 353 (17.3%) |
| 30-39 | 303 (29.2%) | 541 (28.7%) | 620 (30.3%) |
| 40-49 | 298 (28.8%) | 537 (28.5%) | 556 (27.2%) |
| 50-59 | 220 (21.2%) | 440 (23.3%) | 474 (23.2%) |
| 60+ | 19 (1.8%) | 27 (1.4%) | 43 (2.1%) |
| Study site |  |  |  |
| Adelaide | 75 (7.2%) | 130 (6.9%) | 165 (8.1%) |
| Brisbane | 138 (13.3%) | 304 (16.1%) | 357 (17.4%) |
| Melbourne | 97 (9.4%) | 244 (12.9%) | 244 (11.9%) |
| Newcastle | 168 (16.2%) | 429 (22.7%) | 443 (21.7%) |
| Perth | 279 (26.9%) | 345 (18.3%) | 433 (21.2%) |
| Sydney | 279 (26.9%) | 435 (23.1%) | 404 (19.7%) |
| Vaccine history  (# in last 5 years) |  |  |  |
| 0 | 131 (12.6%) | 45 (2.4%) | 61 (3.0%) |
| 1 | 99 (9.6%) | 87 (4.6%) | 57 (2.8%) |
| 2 | 79 (7.6%) | 114 (6.0%) | 115 (5.6%) |
| 3 | 52 (5.0%) | 117 (6.2%) | 122 (6.0%) |
| 4 | 100 (9.7%) | 136 (7.2%) | 185 (9.0%) |
| 5 | 575 (55.5%) | 1388 (73.6%) | 1506 (73.6%) |